SG11202005479QA - System and method for characterizing protein dimerization - Google Patents
System and method for characterizing protein dimerizationInfo
- Publication number
- SG11202005479QA SG11202005479QA SG11202005479QA SG11202005479QA SG11202005479QA SG 11202005479Q A SG11202005479Q A SG 11202005479QA SG 11202005479Q A SG11202005479Q A SG 11202005479QA SG 11202005479Q A SG11202005479Q A SG 11202005479QA SG 11202005479Q A SG11202005479Q A SG 11202005479QA
- Authority
- SG
- Singapore
- Prior art keywords
- protein dimerization
- characterizing protein
- characterizing
- dimerization
- protein
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5032—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on intercellular interactions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Engineering & Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862625732P | 2018-02-02 | 2018-02-02 | |
US201862738051P | 2018-09-28 | 2018-09-28 | |
PCT/US2019/016278 WO2019152796A1 (en) | 2018-02-02 | 2019-02-01 | System and method for characterizing protein dimerization |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202005479QA true SG11202005479QA (en) | 2020-07-29 |
Family
ID=65685942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202005479QA SG11202005479QA (en) | 2018-02-02 | 2019-02-01 | System and method for characterizing protein dimerization |
Country Status (14)
Country | Link |
---|---|
US (3) | US10718754B2 (en) |
EP (1) | EP3746795A1 (en) |
JP (3) | JP7171746B2 (en) |
KR (2) | KR20230008920A (en) |
CN (2) | CN117871866A (en) |
AU (2) | AU2019215125B2 (en) |
BR (1) | BR112020013009B1 (en) |
CA (1) | CA3085625A1 (en) |
IL (1) | IL276102A (en) |
MX (1) | MX2020007991A (en) |
SG (1) | SG11202005479QA (en) |
TW (2) | TW202311746A (en) |
WO (1) | WO2019152796A1 (en) |
ZA (1) | ZA202003546B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202311746A (en) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | System and method for characterizing protein dimerization |
EP4065593A4 (en) * | 2019-11-26 | 2024-04-03 | Merck Sharp & Dohme Llc | On-line ultra performance hydrophobic interaction chromatography for monitoring at least one product attribute |
CA3230317A1 (en) * | 2021-09-14 | 2023-03-23 | Regeneron Pharmaceuticals, Inc. | Nmass spectrometry-based strategy for characterizing high molecular weight species of a biologic |
US20230279046A1 (en) * | 2022-02-25 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Size exclusion chromatography for characterizing host cell proteins |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
GB0131014D0 (en) * | 2001-12-28 | 2002-02-13 | James Peter | Method for molecule-mlecule analysis |
DE60309238T2 (en) | 2002-03-08 | 2007-06-06 | Asml Netherlands B.V. | Lithographic mask, lithographic apparatus and method of making a device |
AU2003231525A1 (en) * | 2002-04-26 | 2003-11-10 | Ajinomoto Co., Inc. | Method of analyzing protein structure, protein structure analyzer, program and recording medium |
ES2592271T3 (en) * | 2005-03-31 | 2016-11-29 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide production methods by regulating the association of polypeptides |
CA2604032C (en) * | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
NZ587107A (en) | 2006-06-02 | 2012-05-25 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
CN101809037B (en) | 2007-07-31 | 2014-01-15 | 瑞泽恩制药公司 | Human antibodies to human cd20 and method of using thereof |
US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
JO3672B1 (en) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | High Affinity Human Antibodies to PCSK9 |
CA2766220C (en) | 2009-06-26 | 2021-02-09 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
US20110151493A1 (en) * | 2009-12-09 | 2011-06-23 | Amgen Inc. | Polypeptide disulfide bond analysis |
JO3417B1 (en) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |
JO3340B1 (en) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | Antibodies to human gdf8 |
KR20130088131A (en) * | 2010-06-16 | 2013-08-07 | 아비에 인코포레이티드 | Comparison of protein samples |
JOP20190250A1 (en) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | Stabilized formulations containing anti-ngf antibodies |
AR083044A1 (en) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | ANTI-CD48 ANTIBODIES AND USES OF THE SAME |
CA2813587C (en) | 2010-10-06 | 2019-01-15 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
JO3756B1 (en) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to the glucagon receptor |
AR087329A1 (en) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | HUMAN ANTIBODIES AGAINST PROTEIN 3 OF HUMAN ANGIOPOIETIN TYPE |
KR102048189B1 (en) | 2011-11-14 | 2019-11-25 | 리제너론 파아마슈티컬스, 인크. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a |
NZ627859A (en) | 2012-01-23 | 2015-09-25 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
JO3820B1 (en) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | Human antibodies to fel d1 and methods of use thereof |
TWI641619B (en) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | Anti-egfr antibodies and uses thereof |
WO2014028354A1 (en) | 2012-08-13 | 2014-02-20 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
JOP20200236A1 (en) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof |
JO3405B1 (en) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF |
JO3532B1 (en) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | Anti-il-33 antibodies and uses thereof |
TWI659968B (en) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | Human antibodies to respiratory syncytial virus f protein and methods of use thereof |
CA2904377C (en) | 2013-03-15 | 2021-07-13 | Regeneron Pharmaceuticals, Inc. | Il-33 antagonists and uses thereof |
TWI641620B (en) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | Anti-prlr antibodies and uses thereof |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
WO2015138460A1 (en) | 2014-03-11 | 2015-09-17 | Regeneron Pharmaceuticals, Inc. | Anti-egfrviii antibodies and uses thereof |
TWI754319B (en) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | Methods and antibody compositions for tumor treatment |
EP3636073B1 (en) | 2014-05-05 | 2023-11-15 | Regeneron Pharmaceuticals, Inc. | Humanized c5 and c3 animals |
JP2017521677A (en) * | 2014-05-21 | 2017-08-03 | リクレイムアールエックス,エルエルシー | Methods for comparing protein conformation |
JO3701B1 (en) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to middle east respiratory syndrome – coronavirus spike protein |
BR112017005110A2 (en) | 2014-09-16 | 2018-01-23 | Regeneron Pharma | isolated monoclonal antibody or antigen-binding fragment thereof, isolated nucleic acid molecule, pharmaceutical composition, and method for lowering blood glucose levels or for treating a condition or disease. |
TWI710573B (en) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | Human antibodies to ebola virus glycoprotein |
CN107037116B (en) * | 2016-12-01 | 2019-04-23 | 白波 | Detect the method for interaction and its interface between GPCR |
TW202311746A (en) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | System and method for characterizing protein dimerization |
-
2019
- 2019-01-31 TW TW111143498A patent/TW202311746A/en unknown
- 2019-01-31 TW TW108103881A patent/TWI786265B/en active
- 2019-02-01 US US16/265,083 patent/US10718754B2/en active Active
- 2019-02-01 CN CN202410062572.6A patent/CN117871866A/en active Pending
- 2019-02-01 AU AU2019215125A patent/AU2019215125B2/en active Active
- 2019-02-01 WO PCT/US2019/016278 patent/WO2019152796A1/en active Application Filing
- 2019-02-01 KR KR1020237000391A patent/KR20230008920A/en not_active Application Discontinuation
- 2019-02-01 CA CA3085625A patent/CA3085625A1/en active Pending
- 2019-02-01 EP EP19709148.1A patent/EP3746795A1/en active Pending
- 2019-02-01 BR BR112020013009-5A patent/BR112020013009B1/en active IP Right Grant
- 2019-02-01 CN CN201980008061.3A patent/CN111630388B/en active Active
- 2019-02-01 KR KR1020207019724A patent/KR102486360B1/en active IP Right Grant
- 2019-02-01 JP JP2020541355A patent/JP7171746B2/en active Active
- 2019-02-01 MX MX2020007991A patent/MX2020007991A/en unknown
- 2019-02-01 SG SG11202005479QA patent/SG11202005479QA/en unknown
-
2020
- 2020-06-12 US US16/899,940 patent/US11525823B2/en active Active
- 2020-06-12 ZA ZA2020/03546A patent/ZA202003546B/en unknown
- 2020-07-16 IL IL276102A patent/IL276102A/en unknown
-
2022
- 2022-11-02 US US17/979,280 patent/US20230110712A1/en active Pending
- 2022-11-02 JP JP2022176190A patent/JP7449351B2/en active Active
-
2023
- 2023-05-05 AU AU2023202820A patent/AU2023202820A1/en active Pending
-
2024
- 2024-03-01 JP JP2024030992A patent/JP2024059930A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3746795A1 (en) | 2020-12-09 |
BR112020013009A2 (en) | 2020-11-24 |
IL276102A (en) | 2020-08-31 |
TW201945384A (en) | 2019-12-01 |
ZA202003546B (en) | 2023-12-20 |
US20190242877A1 (en) | 2019-08-08 |
KR20200116913A (en) | 2020-10-13 |
US11525823B2 (en) | 2022-12-13 |
US20200309768A1 (en) | 2020-10-01 |
TW202311746A (en) | 2023-03-16 |
JP7171746B2 (en) | 2022-11-15 |
AU2019215125B2 (en) | 2023-03-30 |
JP7449351B2 (en) | 2024-03-13 |
US10718754B2 (en) | 2020-07-21 |
CN117871866A (en) | 2024-04-12 |
BR112020013009B1 (en) | 2022-10-25 |
MX2020007991A (en) | 2020-09-09 |
KR102486360B1 (en) | 2023-01-09 |
JP2021512300A (en) | 2021-05-13 |
KR20230008920A (en) | 2023-01-16 |
JP2024059930A (en) | 2024-05-01 |
US20230110712A1 (en) | 2023-04-13 |
AU2019215125A1 (en) | 2020-07-23 |
TWI786265B (en) | 2022-12-11 |
CA3085625A1 (en) | 2019-08-08 |
CN111630388A (en) | 2020-09-04 |
WO2019152796A1 (en) | 2019-08-08 |
CN111630388B (en) | 2024-02-09 |
JP2023022021A (en) | 2023-02-14 |
AU2023202820A1 (en) | 2023-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202006772QA (en) | System and method for decentralized-identifier creation | |
EP3669306A4 (en) | System and method for identifying vaping and bullying | |
GB2572127B (en) | Method and system for agriculture | |
EP3742474C0 (en) | Bonding system and bonding method | |
EP3701066A4 (en) | Methods and systems for protein identification | |
IL276102A (en) | System and method for characterizing protein dimerization | |
IL277194A (en) | Means and methods for glycoprofiling of a protein | |
IL290612A (en) | Systems and methods for predicting proteins | |
IL291284A (en) | Systems and methods for protein expression | |
GB2572677B (en) | System and method | |
GB202115227D0 (en) | Carrier-resolved photo-hall system and method | |
PT3775739T (en) | Freeze-drying system and method therefor | |
SG11202008734WA (en) | Method and system of protein extraction | |
GB201809582D0 (en) | System and method | |
GB201808878D0 (en) | Optimisation system and method | |
IL257059B (en) | Multi-beamforming system and method | |
ZA202001260B (en) | System and method for injecting an egg | |
SG11202009372UA (en) | Systems and methods for quantifying and modifying protein viscosity | |
GB201816668D0 (en) | System and method | |
SG10201808304WA (en) | System and method for identifying veins | |
GB201812593D0 (en) | Illimination system and method | |
GB201817593D0 (en) | An ATM-requesting-and-accessing system and method | |
GB201703416D0 (en) | Method for protein expression | |
ZA201907240B (en) | Panelisation system and method | |
PL3821200T3 (en) | Oct system and oct method |